drugset / Trial / NCT00648661

Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg

NCT00648661

Phase 1 Completed 35 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's escitalopram oxalate 20 mg tablets to Forest's Lexapro® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administered under fed conditions.

Timeline

Start
2004-09
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg Oral

Indications

No indication recorded.